Omeprazole disposition in children following single-dose administration

Journal of Clinical Pharmacology

Volumn 43, Issue 8, 2003, Pages 840-848

  Kearns, Gregory L ^a,b,c   Andersson, Tommy ^d   James, Laura P ^e,f   Gaedigk, Andrea ^c   Kraynak, Rebecca A ^d   Abdel Rahman, Susan M ^a,c   Ramabadran, Krishnaswami ^d   Van den Anker, John N ^g,h  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f ARKANSAS CHILDREN S HOSPITAL   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

CYP2C19 genotype; Gastroesophageal reflux; Omeprazole; Pediatrics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE;

ADOLESCENT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INDICATION; DRUG METABOLISM; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMERASE CHAIN REACTION;

EID: 0037961049     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003256122     Document Type: Article

References (27)

1. Andersson T: Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
2. Stedman CAM, Barclay ML: Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-978.
3. Zimmermann AE, Walters JK, Katona BG, Souney PE, Levine D: A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 2001;23:660-679.
4. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L: Stereoselective metabolism of omeprazole by human cytochromes P450 enzymes. Drug Metab Dispos 2000;28:966-972.
5. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, et al: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001;18:721-727.
6. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, et al: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001;15:1929-1937.
7. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R: Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000;119:670-676.
8. Kita T, Tanigawara Y, Aoyama N, Hohda T, Saijoh Y, Komada F, et al: CYP2Cl9 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res 2001;18:615-621.
9. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M: Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001;33:671-675.
10. Leeder JS: Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am 2001;48:765-781.
11. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, et al: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999;290:635-640.
12. CYP2C19 allele nomenclature. Retrieved from http://www.imm.ki.se/CYPalleles/cyp2c19.htm
13. Goldstein JA, de Morais SMF: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1999;9:669-682.
14. Hassall E, Israel D, Shepherd R, Radke M, Dalvag A, Skold B, et al: Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000;137:800-807.
15. Jacqz-Aigrain E, Bellaich M, Faure C, Andre J, Rohrlich P, Baudouin V, et al: Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 1994;47:181-185.
16. Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, et al: Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000;95:3101-3106.
17. Faure C, Michaud L, Shaghaghi EK, Popon M, Turck D, Navarro J, et al: Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr 2001; 33:144-148.
18. Tamminga WJ, Wemer J, Oosterhuis B, Brakenhoff JP, Gerrits MG, deZeeuw RA, et al: An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol 2001;57:143-146.
19. Zhou HH: CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 2001; 313:203-208.
20. Woolf EJ, Matuszewski BK: Simultaneous determination of omeprazole and 5′-hydroxyomeprazole in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1998;828(1-2):229-238.
21. Stubbins MJ, Marries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the human cytochromes P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-439.
22. Goldstein JA, Blaisdell J: Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Meth Enzymol 1996;272:210-217.
23. Andersson T, Cederberg C, Regardh C-G, Skanberg I: Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 1990;39:195-197.
24. Howden CW: Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991;20:38-49.
25. Leeder JS, Kearns GL: Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin North Am 1997;44:55-77.
26. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364:551-557.
27. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology: the impact of ontogeny on drug disposition and action. N Engl J Med; revised manuscript in preparation, 2002.